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Peroxisome proliferator-activated receptor-gamma (PPAR-γ) is a member of the nuclear receptor (NR) superfamily of ligand-
activatedtranscriptionalfactors.Amongotherfunctions,PPAR-γ actsasakeyregulatoroftheadipogenesis.Sinceseveralcytokines
(IL-1, TNF-α,T G F - β) had been known to inhibit adipocyte diﬀerentiation in mesenchymal stem cells (MSCs), we examined the
eﬀect of these cytokines on the transactivation function of PPAR-γ. We found that the TNF-α/IL-1-activated TAK1/TAB1/NIK
(NFκB-induciblekinase)signalingcascadeinhibitedboththeadipogenesisandTro-inducedtransactivationbyPPAR-γ byblocking
the receptor binding to the cognate DNA response elements. Furthermore, it has been shown that the noncanonical Wnts are
expressed in MSCs and that Wnt-5a was capable to inhibit transactivation by PPAR-γ. Treatment with Wnt5a-activated NLK
(nemo-like kinase) induced physical association of the endogenous NLK and H3K9 histone methyltransferase (SETDB1) protein
complexes with PPAR-γ. This resulted in histoneH3K9 tri-methylation at PPAR-γ target gene promoters. Overall, our data show
that cytokines and noncanonical Wnts play a crucial role in modulation of PPAR-γ regulatory function in its target cells and
tissues.
1.Introduction
Peroxisome proliferator-activated receptor-gamma (PPAR-
γ) belongs to the nuclear receptor (NR) superfamily and
regulates target gene mRNA expression in the ligand-
dependent manner [1]. Similar to most known NRs, PPAR-
γ contains distinct domains for binding the DNA (DBD),
ligand (LBD), and various cofactor complexes. The structure
of PPAR-γ LBD consists of 12 α-helices and 4 β-sheets [2].
For ligand-dependent transcriptional control by PPAR-
γ, several distinct classes of transcriptional coregula-
tors/coregulator complexes are indispensable in addition to
basic transcription machinery to reorganize chromatin state
at the genomic target loci [1, 3]. Transcriptional coregulators
for NRs can be divided into two classes in regard to the
mechanisms of chromatin reorganization. One class consists
of histone modifying enzymes that reversibly modify the N-
terminal tails of nucleosomal histone proteins [4, 5]. For
example, acetylation and methylation at histone H3K4 and
H3K36 are chromatin activating modiﬁcations and support
transcriptional up-regulation by NRs [6, 7]. In contrast,
transcriptional repression by NRs is coupled with inacti-
vating modiﬁcations like deacetylation and methylation at
histone H3K9 and H3K27 [8]. Accordingly, cognate histone
modifying enzymes serve as NR coregulators.
The other class of transcriptional coregulators includes
chromatin remodeling factors that directly reorganize nucle-
osomal arrays using ATP hydrolysis as a source of energy
[9, 10]. Chromatin remodelers function as multi-subunit
complexes and include ATPase catalytic subunits. Four dis-
tinct types of chromatin remodeling complexes (SWI/SNF,
ISWF, WINAC, and NURD) have been so far identiﬁed as
transcriptional coregulators of NRs [11, 12].
Besides ligand dependency, various signaling pathways
modulate the ligand-dependent transactivation function of
NRs.Forexample,phosphorylationintheN-terminalregion
of estrogen receptor alpha (ER-α) by certain pathway-
activated protein kinases enhances the transactivation func-
tion of ER-α [13]. The transcriptional activity of PPAR-γ is
also modulated through positive and negative crosstalk with2 PPAR Research
other signaling pathways [14]. The molecular mechanisms
of the crosstalk include direct and indirect associations of
PPAR-γ with intracellular signal transducers or transcrip-
tional factors as well as covalent modiﬁcations of PPAR-
γ protein, such as phosphorylation by signal-dependent
proteinkinases[15]orsumoylationbyUBC9[16].Phospho-
rylation of PPAR-γ in the N-terminal domain suppresses the
transactivation function of PPAR-γ by reducing aﬃnity for
PPAR-γ ligands[17],whereasligand-dependentsumoylation
of PPAR-γ represses the NF-κB activation and antagonizes
inﬂammatory responses [16]. These clearly indicate that
modiﬁcations in the PPAR-γ molecule play a pivotal role in
modulation of its physiological action (Figure 1).
2.SignalingCrosstalkbetweenPPAR-γ
andCytokinesinMSCs
Mesenchymal stem cells (MSCs) derived from various adult
tissues have the potential to diﬀerentiate into diﬀerent
lineages, including osteoblasts, chondrocytes, adipocytes, or
myocytes [19–21]. Reﬂecting such pluripotency, a number
of regulators involved in the control of MSC diﬀerentiation
have been identiﬁed and characterized [19]. Bone mor-
phogenetic protein (BMP) signaling molecules (particularly
BMP-2, -4, -6, and -7) act as major osteogenic inducers and
may also inﬂuence adipocyte diﬀerentiation [22] through
induction of PPAR-γ corepressor, TAZ [23]. Recently, the
hedgehog signaling has been shown to inhibit adipogenesis
and induce osteoblastogenesis [24].
Since several cytokines (IL-1, TNF-α,T G F - β) inhibit
adipocyte diﬀerentiation in MSC, we examined the eﬀect
of their signaling on the transactivation function of
PPAR-γ.T r e a t m e n tw i t hT N F - α or IL-1 inhibited Tro-
induced transcriptional activity of PPAR-γ. Interestingly,
treatment with both Tro and cytokine (IL-1 or TNF-α)
induced osteoblastogenesis in ST2 cells. Thus, cytokines and
activated PPAR-γ appeared to stimulate cytodiﬀerentiation
of bone marrow progenitor cells into osteoblasts, in
addition to cytokine-dependent interference with adipocyte
diﬀerentiation. Since TNF-α and IL-1 are known to activate
the NF-κB in the nucleus, and the nuclear NF-κBi s
indispensable for osteoclastogenesis from heamatopoetic
stem cells, these cytokines appear to be physiologically
important for the mesenchymal stem cell fate decision. We
therefore studied eﬀects of downstream mediators of the
TNFα/IL-1 signaling on the MSC diﬀerentiation [14].
In ST2 cells, the TNF-α/IL-1-activated TAK1/TAB1/NIK
(NFκB-inducible kinase) signaling cascade inhibited both
the adipogenesis and Tro-induced transactivation by PPAR-
γ. Though it was previously reported that phosphorylation
of PPAR-γ by MAP kinase resulted in repression of the
PPAR-γ function [15], we showed that TNF-α/IL-1-induced
inhibition of PPAR-γ did not involve its phosphorylation by
the NIK.
Consistent with suppression of the PPAR-γ-depend-
ent luciferase reporter gene activity, the activated
TAK1/TAB1/NIK was found to suppress the Tro-induced
expression of endogenous PPAR-γ target genes. We found
that treatment with these cytokines or ectopic expression
of some of their downstream mediators blocked binding of
PPAR-γ to its response element DNA sequences (PPRE) in
the target gene promoters (Cbl-associated protein, CAP).
CAP is a signaling protein that interacts with both c-Cbl
and the insulin receptor that may be involved in the speciﬁc
insulin-stimulated tyrosine phosphorylation of c-Cbl
[25, 26]. Next, we have shown that the TAK1/TAB1/NIK
pathway-activatedNF-κBblockstheDNAbindingofPPAR-γ
at the PPRE. Together with the previous reports that agonist-
activated PPAR-γ inhibits DNA binding by NF-κB[ 27], it
appears that an association of ligand-activated PPAR-γ with
nuclear NF-κB results in a complex incapable to interact
with DNA at either corresponding binding sites (Figure 2).
Thus, we presume that TNF-α/IL-1 triggers activation
of NF-κB through the TAK1/TAB1/NIK axis, leading to a
physical association between PPAR-γ and NF-κB thereby
inhibiting the ligand-dependent PPAR-γ transactivation.
Since PPAR-γ is a prime regulator of adipogenesis,
suppressionofthePPAR-γ functionmayinhibitadipogenesis
and consequently, shift the bone marrow cell fate decision
towards the osteoblastogenesis [14].
3. Noncanonical Wnt SignalingInduces
Osteoblastogenesis through Transrepression
of PPAR-γ by Histone
Methyltransferase Complex
Our recent studies of the eﬀects of Wnts on the osteoblas-
togenesis and adipogenesis have shown that Wnt signaling
may directly regulate the transactivation function of PPAR-γ
in the MSCs [28]. Several frizzled receptors and Wnt ligands
have been found expressed at signiﬁcant levels in the ST2
cells and in mouse bone marrow cell primary culture. Inter-
estingly, noncannonical Wnt ligand (Wnt-5a) and receptors
(Frizzled-2 and -5) were found to be expressed in these cells
at particular high levels [28]. While Wnt-3a, a canonical
Wnt ligand, did not aﬀect transactivation function of Tro-
induced PPAR-γ, noncanonical Wnt-5a was capable to
repress activation by PPAR-γ recombinant and endogenous
PPAR-γ target gene promoters. We then explored an ability
of downstream mediators of the Wnt-5a signaling to repress
PPAR-γ anddeterminedthatCaMKII-TAK1/TAB2-NLKaxis
members were potent inhibitors of the receptor. This was
consistent with reports that NLK-deﬁcient mice exhibited
increased adipocyte concentration in the bone marrow [29].
As the NLK acts as a downstream mediator in the Wnt-
5a signaling pathway, we explored molecular basis of the
transrepressive eﬀects of NLK on the PPAR-γ transcriptional
function. Since tricostatine A, an inhibitor of a wide
range of HDACs, was unable to reverse the NLK-mediated
suppression of PPAR-γ function, this opened a question
about possible involvement of other inactivating histone
modifying enzymes. NLK-containing protein complexes
were biochemically puriﬁed from nuclear extracts of KCl-
treated HeLa cells expressing FLAG-tagged NLK [9, 30]a n dPPAR Research 3
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Figure 1: Structure and posttranslational modiﬁcations of PPAR-γ1, -γ2 proteins. Although PPAR-γ was ubiquitinated, lysine residues are
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Figure 2: Schema of the proposed molecular mechanism of
adipogenesis inhibition by TNF-α and IL-1 through suppression
of PPAR-γ function by NF-κB activated via the NIK-TAK1/TAB1-
mediated cascade.
a distinct NLK-nuclear protein complex with a molecular
weightofaround400–500kDawasisolatedandanalysed[28,
31]. In this complex, a 170kDa component was identiﬁed
as a SETDB1, a transcription inhibiting histone lysine-
methyltransferase (HKMT) that methylates histone H3 at K9
[32, 33]. Importantly, in ST2 cells, treatment with Wnt5a
induced a physical association of endogenous NLK-SETDB1
protein complexes with PPAR-γ.
ChIP analysis of endogenous transcriptional factors
and histone modiﬁcations at the PPAR-γ response element
(PPRE) in the aP2 gene promoter [34] has shown that
treatment with Tro induced recruitment of known PPAR-γ
coactivator SRC-1. However, simultaneous treatment with
Wnt-5a and Tro induced recruitment of NLK and SETDB1
at the PPRE region. Consistently, an increase in histone H3
di-andtri-methylationatK9wasobservedtogetherwithhis-
tone hypoacetylation. Such coordinated chromatin silencing
histone modiﬁcations at the PPAR-γ target genes were more
prominent after a 7-day treatment with Wnt-5a that was
long enough to induce the osteoblastogenesis. Furthermore,
an ectopic expression of either NLK or SETDB1 in the
presence of Tro was potent to induce the osteoblastogenesis
and inhibit the adipogenesis, whereas a knockdown of either
NLK or SETDB1 potentiated the Tro-induced adipogenesis
even in the presence of Wnt-5a. Thus, we have shown that
Wnt-5a induces the osteoblastogenesis through attenuating
the PPAR-γ-induced adipogenesis in the bone marrow MSC
(Figure 3).
Upon Wnt-5a-induced activation of the noncanonical
Wnt signaling, the SETDB1 HKMT forms a complex with
phosphorylatedNLK.ThisNLK/SETDB1complexassociates
with PPAR-γ and methylates H3-K9 at the PPAR-γ target
gene promoters leading to their transcriptional silencing.
Interestingly, the NLK also suppresses the transactivation
function of the A-Myb through histone methylation [35],
suggesting that the NLK might control gene expression by
histone modiﬁcation through recruitment of SETDB1.
The noncanonical Wnt-5a ligand regulates MSC diﬀer-
entiation through the CaMKII-TAK1/TAB2-NLK signaling
cascade that is distinct from the canonical Wnt pathway,
which is mediated by the β-catenin/TCF signal transduc-
tion. Several recent reports have demonstrated that the
canonical Wnt pathway mediated by LRP5/β-catenin is also
indispensable for the osteoblastogenesis [36–38]. Hence,
both the canonical and noncanonical Wnt pathways are
considered to support the osteoblastogenesis in the bone
marrow mesenchymal cells. However, only the noncanonical
Wnt signaling appears to impair the PPAR-γ-inducible
adipogenesis and switch the MSC diﬀerentiation into the
osteoblastic lineage.4 PPAR Research
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Figure 3: Schematic model of crosstalk between PPAR-γ and Wnt-5a signaling in MSC. NLK activated by the Wnt5a signaling pathway
phosphorylates SETDB1 and forms a complex with PPAR-γ/RXR and chromodomain containing protein 7 (CHD7).
4. Conclusion
In summary, IL-1, TNF-α, and noncanonical Wnt signaling
pathways suppress the PPAR-γ function in MSCs and thus,
are capable to inﬂuence stem cell fate [39]. Interestingly,
molecular mechanism of suppression of the PPAR-γ tran-
scriptional activity by the IL-1 and TNF-α is diﬀerent from
that induced by the noncanonical Wnt ligands. IL-1 or TNF-
α-activated NF-κB inhibits the DNA binding capacity of
the receptor, while Wnt5a-activated NLK promotes PPAR-
γ/SETDB1complexformationleadingtosilencingepigenetic
chromatin modiﬁcations at the PPRE. Recent studies show
that PPAR-γ also plays pivotal roles in other cells and tissues,
such as osteoclasts [40], kidney cells [41], and macrophages
[27]. This opens questions about the existence of other
mechanisms of modulations of the PPAR-γ physiological
activityspeciﬁcforthesetypesofdiﬀerentiatedcellsthatmay
be diﬀerent from those in stem cells.
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